Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $22
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $18 to $22.
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $18 to $22.